ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2014
Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.
Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.JCO precision oncology · 2021Trial
- A multigene array for measurable residual disease detection in AML patients undergoing SCT.Bone marrow transplantation · 2015Trial
- Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.Bone marrow transplantation · 2025Article
- Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.Bone marrow transplantation · 2025Article
- Allogeneic transplantation for advanced acute leukemia.Hematology. American Society of Hematology. Education Program · 2022Article
- Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML.Blood advances · 2021Article
- Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.Journal of translational medicine · 2017Article
- GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.Current drug targets · 2017Review
- Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Review
- Precision medicine for acute myeloid leukemia.Expert review of hematology · 2016Article
- Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects.Bone marrow transplantation · 2015Review
- Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Article
- Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.Bone marrow transplantation · 2015Review
- Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.Seminars in hematology · 2015Review
- Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Journal of clinical medicine · 2015Article
- Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.OncoTargets and therapy · 2015Review
- Next generation MRD.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014Article
- Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.Current treatment options in oncology · 2014Review
- Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Current hematologic malignancy reports · 2014Review
Corrections and comments
- Reprinted as
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Relapse is a devastating event for patients with hematologic cancers treated with hematopoietic stem cell transplantation. In most situations, relapse treatment options are limited. Maintenance therapy offers the possibility of delaying or avoiding disease recurrence, but its role remains unclear in most conditions that we treat with transplantation. Here, Dr. Hourigan presents an overview of minimal residual disease (MRD) measurement in hematologic malignancies and the applicability of MRD-based post-transplantation interventions. Dr. McCarthy reviews current knowledge of maintenance therapy in the autologous transplantation context, with emphasis on immunologic interventions and immune modulation strategies designed to prevent relapse. Dr. de Lima discusses current lines of investigation in disease recurrence prevention after allogeneic transplantation, focusing on acute myeloid leukemia and myelodysplastic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.